CGEMCullinan Oncology, Inc.

Nasdaq cullinanoncology.com


$ 23.25 $ 0.28 (1.22 %)    

Tuesday, 11-Jun-2024 15:59:55 EDT
QQQ $ 468.10 $ 3.19 (0.69 %)
DIA $ 388.08 $ -1.32 (-0.34 %)
SPY $ 537.01 $ 1.29 (0.24 %)
TLT $ 91.83 $ 0.94 (1.03 %)
GLD $ 214.15 $ 0.61 (0.29 %)
$ 23.25
$ 22.21
$ 0.00 x 0
$ 0.00 x 0
$ 22.21 - $ 23.98
$ 7.64 - $ 30.19
634,573
na
1B
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-09-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-cullinan-therapeutics-maintains-28-price-target

HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $28 pri...

 reported-saturday-cullinan-therapeutics-announced-initial-data-from-pivotal-phase-2b-rezilient1-study-of-zipalertinib

As of a January 12, 2024 data cut-off, 31 patients had been enrolled. Patients had received a median of three prior systemic an...

 hc-wainwright--co-reiterates-buy-on-cullinan-therapeutics-maintains-28-price-target

HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $28 pri...

 cullinan-therapeutics-files-for-resale-of-up-to-144m-shares-by-the-selling-stockholders

- SEC Filing

 hc-wainwright--co-maintains-buy-on-cullinan-therapeutics-lowers-price-target-to-28

HC Wainwright & Co. analyst Edward White maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and lowers the price t...

 wedbush-reiterates-outperform-on-cullinan-therapeutics-maintains-36-price-target

Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $36 price tar...

 stifel-initiates-coverage-on-cullinan-therapeutics-with-buy-rating-announces-price-target-of-40

Stifel analyst Bradley Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Pric...

 why-is-cullinan-therapeutics-stock-trading-higher-on-wednesday

Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN...

 cullinan-therapeutics-to-present-clinical-data-from-phase-1-study-evaluating-novel-anti-micab-antibody-cln-619-as-monotherapy-and-in-combination-with-a-checkpoint-inhibitor-in-patients-with-advanced-solid-tumors-at-asco-2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today a...

 why-travelers-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

 btig-maintains-buy-on-cullinan-oncology-raises-price-target-to-30

BTIG analyst Kaveri Pohlman maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and raises the price target from $20 to $30.

 united-airlines-reports-upbeat-results-joins-childrens-place-interactive-brokers-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday.

 hc-wainwright--co-maintains-buy-on-cullinan-oncology-lowers-price-target-to-29

HC Wainwright & Co. analyst Edward White maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and lowers the price targe...